Andersons pediatric cardiology 2365
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (80.21 KB, 3 trang )
MobitztypeIIAVblock,337–338,337f
m-O-dealkyaltedlactam(MODLF),1437
m-O-dealkylatedflecainide(MODF),1437
ModifiedBlalock-Taussigshunt,1278–1279,1278f
ModifiedFontanprocedure,1300–1304,1300b
decisionmakingin,1301–1303
postoperativeconsiderationsin,1303–1304,1303b
bedsidepreparednessandmonitoring,1303
effusions/chylothorax,1304
lowcardiacoutputin,1303–1304,1304t
positive-pressureventilation,1303
rhythmdisturbances,1304
preoperativeevaluationin,1300,1300t
surgicalstrategiesin,1300–1301,1301f–1302f
Monogenicsyndromes,1412–1419
Adams-Oliversyndrome,1417,1417t
Alagillesyndrome,1416,1416t
Chargesyndrome,1417,1417t
Ellis-vanCreveldsyndrome,1414–1415,1414f,1414t
Goldenharsyndrome,1418–1419,1418t
Holt-Oramsyndrome,1416–1417,1416f,1416t
Kabukisyndrome,1415–1416,1415f,1415t
RASopathies(Noonansyndromeandrelateddisorders),1412–1414,1413f,1413t
VACTERLassociation,1417,1418f,1418t
Monomorphicventriculartachycardia,350–351,351f
Moraldistress,1474–1475,1475b
Moraldiversity,culturaland,1471,1471t
Moralresilience,1474–1475,1475b
keycharacteristicsof,1475b
Morphologicmethod,441
Morquiosyndrome,cardiacinvolvementin,1091
Mortality
followingtransplantation,1218–1219,1222f–1224f
causesofdeathand,1221,1225t,1226f
riskfactorsfordeathand,1219–1220,1224t–1225t
inFontancirculation,foruniventricularheart,1318
neonatal
accordingtobirth,190t
inprematurity,211
rate,definitionof,190b
whileawaitingcardiactransplantation,1217–1218
Mother,optimizingprenatalsupportof,163–170
Mousemyocardialdevelopment,61,62f
MRI,Magneticresonanceimaging
Mucocutaneouslymphnodesyndrome,979
Mucolipidoses,cardiacinvolvementin,1091–1092
Mucopolysaccharidoses,cardiacinvolvementin,1089–1091
MUGA,Multigatedradionuclideangiography
MulticenterPediatricandAdultCongenitalEPQualityRegistry,1511t–1514t
Multidisciplinaryteam,1481
Multidistributioncirculation,1264
Multidrugresistance,1528
Multifocalatrialtachycardia(MAT),349,349f
Multigatedradionuclideangiography(MUGA),forcancertherapy-related
cardiotoxicity,1171
Multitracksystem,1035,1036t
Murmurs
inEbsteinmalformation,591
ininteratrialcommunication,511
Musclephosphofructokinase1deficiency,cardiacinvolvementin,1089
Musclephosphorylasedeficiency,cardiacinvolvementin,1089
Musculardystrophies,cardiacinvolvementin,1102–1105
Mustardprocedure,fortranspositionofthegreatarteries,686
Myocardialactivation,incardiacmyocyte,1197
Myocardialbridging,869
Myocardialdevelopment,59–82
cellbiologywithhumandisease,77–82
Barthsyndrome(BTHS),80–81
Danondisease(DD),80
Duchennemusculardystrophy,77–80,78f
hypertrophiccardiomyopathy,77
precisionmedicinein,81–82
celltypesin,62–66
cardiomyocyte,62,63f
endothelialcells,65–66
fibroblasts,62–64,63f–64f
vascularsmoothmusclecells,64–65,65f
early,59–62
atrialandventricularseptationin,60–61
atrioventricularvalvesformationin,61
cardiacloopingin,59–60,60f
humanandmouse,comparisonof,61,62f
outflowtractandsemilunarvalvedevelopmentin,61
structuralheartdiseaseoriginin,61–62
regeneration,66–67
Myocardialdysfunction,inprematurity,201
Myocardialfibrosis,450
Myocardialfunction,regulationof,prematurityand,191–192
Myocardialinfarction,450
inKawasakidisease,984
premature,systemicarterialdysfunctionand,1371
Myocardialischemia,evaluationof,exercisetestingfor,391,394
Myocardialprotection,incardiopulmonarybypass,230
Myocarditis,1173–1178,1522–1523
autoimmune,1178
autoinflammatory,1178
cardiacmagneticresonancein,1175,1177f
